These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 2031512)
1. A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma. Errante D; Sorio R; Zagonel V; Carbone A; Monfardini S; Tirelli U Am J Clin Oncol; 1991 Jun; 14(3):243-5. PubMed ID: 2031512 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma. Case DC; Hayes DM; Gerber M; Gams R; Ervin TJ; Dorsk BM Cancer Res; 1990 Nov; 50(21):6833-5. PubMed ID: 2208149 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma. Case DC; Gerber MC; Gams RA; Crawford J; Votaw ML; Higano CS; Pruitt BT; Gould J Cancer Res; 1992 Jul; 52(14):3871-4. PubMed ID: 1617662 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma. Zinzani PL; Pulsoni A; Gentilini P; Visani G; Perrotti A; Molinari AL; Guardigni L; Tani M; Villivà N; Stefoni V; Alinari L; Martelli M; Bonifazi F; Pileri S; Tura S; Baccarani M Leuk Lymphoma; 2004 Sep; 45(9):1815-9. PubMed ID: 15223641 [TBL] [Abstract][Full Text] [Related]
5. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Taylor PR; White JM; Prescott RJ; Angus B; Galloway MJ; Jackson GH; Lessells AM; Lucraft HH; Summerfield GP; Proctor SJ; Leuk Lymphoma; 2006 Nov; 47(11):2321-30. PubMed ID: 17107904 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma. Case DC; Gerber MC; Gams RA; Crawford J; Votaw ML; Higano CS; Pruitt BT; Gould J Leuk Lymphoma; 1993; 10 Suppl():73-9. PubMed ID: 8481674 [TBL] [Abstract][Full Text] [Related]
7. Oral idarubicin in non-Hodgkin's lymphomas. Lopez M; Di Lauro L; Papaldo P Invest New Drugs; 1986; 4(3):263-7. PubMed ID: 3469170 [TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators. Morra E; Gargantini L; Nosari A; Barbarano L; Pungolino E; Santoleri L; Bernuzzi P Crit Rev Oncol Hematol; 2000 Aug; 35(2):95-100. PubMed ID: 10936466 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of oral idarubicin in elderly patients with advanced breast cancer. Chevallier B; Monnier A; Metz R; Namer M; Marty M; Roche H; Bastit P; Hurteloup P Am J Clin Oncol; 1990 Oct; 13(5):436-9. PubMed ID: 2220664 [TBL] [Abstract][Full Text] [Related]
10. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. Reiser M; Schnell R; Straub G; Borchmann P; Wilhelm M; Ubelacker R; Wörmann B; Münch R; Diehl V; Engert A Leuk Lymphoma; 1998 Oct; 31(3-4):359-66. PubMed ID: 9869200 [TBL] [Abstract][Full Text] [Related]
11. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Zinzani PL; Martelli M; Storti S; Musso M; Cantonetti M; Leone G; Cajozzo A; Papa G; Iannitto E; Perrotti A Leuk Lymphoma; 1995 Oct; 19(3-4):329-35. PubMed ID: 8535227 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma. Salman H; Perez A; Sparano JA; Ratech H; Negassa A; Hopkins U; Villani G; Fuks J; Wiernik PH Am J Clin Oncol; 2003 Aug; 26(4):338-43. PubMed ID: 12902881 [TBL] [Abstract][Full Text] [Related]